99% antidepressants Pharmaceutical powder Duloxetine hydrochloride 136434-34-9

Model NO.: CAS: 136434-34-9
CAS: 136434-34-9
Molecular Formula: C18H19NOSHCl
Grade: Pharmaceutical Grade
Categories: Oral
Package: Foil bag
Use: antidepressants
Market: Global
Delivery Time: About 3 days
Trademark: ZZYCH
Transport Package: Foil Bag or as Requirement
Specification: Foil bag
Origin: China
Model NO.: CAS: 136434-34-9
CAS: 136434-34-9
Molecular Formula: C18H19NOSHCl
Grade: Pharmaceutical Grade
Categories: Oral
Package: Foil bag
Use: antidepressants
Market: Global
Delivery Time: About 3 days
Trademark: ZZYCH
Transport Package: Foil Bag or as Requirement
Specification: Foil bag
Origin: China
99% antidepressants Pharmaceutical powder Duloxetine Hydrochloride 136434-34-9


Product name:(S)-N,N-Dimethyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hydrochloride
CAS number: 136434-34-9
Molecular Formula: C18H19NOS·HCl
Molecular weight: 333.88
Appearance: white or almost white crystalline powder
Solubility: Slightly soluble in water, easily soluble in methanol, almost insoluble in n-hexane
Loss on drying: ≤0.5%
Sulphated Ash: ≤0.1%
Heavy metal: ≤20ppm
Specific rotation: +118~+123o
Content (HPLC): ≥99.0%
Single impurity: ≤ 0.1
Chiral isomer: ≤ 0.5%
The main purpose: antidepressants


Use
Duloxetine hydrochloride/Cymbaha (hereinafter referred to as duloxetine) is a 5-hydroxytryptamine and norepinephrine reuptake inhibitor developed by Eli Lilly. 5 Both serotonin and norepinephrine are central neurotransmitters and play an important role in regulating emotion and sensitivity to pain. Duloxetine can inhibit the reuptake of neurons to serotonin and norepinephrine, thereby increasing the concentration of these two central neurotransmitters in the brain and spinal cord. It can be used to treat certain mood disorders such as depression. And anxiety disorders and relieve central pain such as diabetic peripheral neuropathy pain and fibromyalgia in women. Duloxetine can also act on the 5-hydroxytryptamine and norepinephrine receptors in the urethra, thereby enhancing the neurological tone and contractility of the urinary sphincter, and is therefore effective in the treatment of stress urinary incontinence in women. Duloxetine is an oral enteric-coated capsule preparation. It was first approved in the United States in August 2004 and has now been marketed in more than 70 countries. The global sales of duloxetine exceeded US$1.3 billion in 2006, and its sales in 2007 and 2008 increased significantly to US$2.1 billion and US$2.7 billion, respectively, making it one of the fastest-growing drugs in the world in recent years. .


Application
In August and December 2004, the United States and the European Union approved duloxetine for the treatment of major adult depression. This is the first indication that duloxetine is officially approved for clinical use. A total of 512 subjects randomized, double-blind, placebo-controlled, pivotal study j1 showed that duloxetine was significantly lower than placebo at 17 weeks with 60 nag once-daily nausea. The total score of the table (tlDRS-17), and significantly improved depressive symptoms after 1 wk of treatment. Another study of 478 patients with severe depression in China, South Korea, and Other countries confirmed that the efficacy of duloxetine 60 mg once a day to relieve depressive symptoms is at least comparable to the most commonly used selective serotonin reuptake One paroxetine/Paxii 20 mg/d was inhibited with fewer side effects (smaller) and did not cause weight gain and sexual dysfunction in the patient. In addition, duloxetine can also significantly improve physical symptoms in patients with depression, including insomnia, bradykinesia, pain, and headaches, which are usually those that cannot be achieved with the use of serotonin reuptake inhibitors. Duloxetine is expected to replace the serotonin reuptake inhibitor as a first-line choice for the treatment of major depression.


Taboo
Duloxetine metabolizes CYP2D6 and CYP1A2, moderately inhibits CYP2D6, but does not inhibit or induce CYP1A2 and CYP3A4. Care should be taken with other drugs that are primarily metabolized by CYP2D6 and have a narrow therapeutic window (eg, TCAs, Class Ic antiarrhythmic drugs, phenothiazines).
1. Disable patients who are known to be allergic to duloxetine or any inactive ingredient in the product. 2. The use of monoamine oxidase inhibitors must not be used in conjunction with the use of monoamine oxidase inhibitors. It is also not possible to use this product within 14 days after the withdrawal of monoamine oxidase inhibitors; according to the half-life of duloxetine, the use of MAOIs can be started at least 5 days after the withdrawal of duloxetine. 3. Clinically indicated that duloxetine increases the risk of dilated pupils, so patients with uncontrolled angle-closure glaucoma should avoid using duloxetine.


Competitive Advantage:

1. Best prices with satisfied quality, great quality and purity.
2. Perfect packing, rich experienced and safe, fast delivery.
3. Enough stock ensure the prompt delivery time .
4. Good after-sales service.


Others offering:
Tasimelteon/ Hetlioz 609799-22-6
Diphenhydramine HCl 147-24-0
Doxylamine Succinate 562-10-7
Melatonin 73-31-4
Zaleplon 151319-34-5
Suvorexant 1030377-33-3
Duloxetine HCl/ Cymbalta 136434-34-9
Quetiapine Fumarate/ Seroquel 111974-72-2
Bupropion HCl 31677-93-7
Citalopram Hydrobromide/ Celexa 59729-32-7
Escitalopram 219861-08-2
Fluvoxamine Maleate/ Luvox 61718-82-9
Paroxetine HCl/ PX/ POTH 78246-49-8
N-Methyl Paroxetine 110429-36-2
Zoloft/ Sertraline HCl 79559-97-0
Fluoxetine HCl/ Prozac 59333-67-4/56296-78-7
Clonidine HCl 4205-91-8
Mirtazapine/ Remeron 85650-52-8/ 61337-67-5
Armodafinil 112111-43-0
Tianeptine Sodium  30123-17-2
Tianeptine/ Stablon 66981-73-5
Tianeptine Sulfate 1224690-84-9
   
Trazodone HCl/ Desyrel 25332-39-2
Agomelatine 138112-76-2
Atomoxetine/ Strattera 82248-59-7
Amitriptyline HCl/ Elavil/ Endep 549-18-8
Reboxetine Mesylate 71620-89-8
Vilazodone 163521-12-8
Vilazodone HCl/ Viibryd 163521-08-2
Vortioxetine/ Trintellix/ Brintellix/ Lu AA21004 508233-74-7
Vortioxetine hydrobromide 960203-27-4
Milnacipran Hydrochloride/ Ixel/ Savella 101152-94-7
Levomilnacipran/ Fetzima 96847-55-1
Desvenlafaxine/ Pristiq (98%) 93413-62-8
Venlafaxine HCl/ Efexor XR 99300-78-4


Welcome inquiry and order samples, i'm Amy, if you want know more details, pls send email me

  99% antidepressants Pharmaceutical powder Duloxetine hydrochloride 136434-34-9


Product name:(S)-N,N-Dimethyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hydrochloride
CAS number: 136434-34-9
Molecular Formula: C18H19NOS·HCl
Molecular weight: 333.88
Appearance: white or almost white crystalline powder
Solubility: Slightly soluble in water, easily soluble in methanol, almost insoluble in n-hexane
Loss on drying: ≤0.5%
Sulphated Ash: ≤0.1%
Heavy metal: ≤20ppm
Specific rotation: +118~+123o
Content (HPLC): ≥99.0%
Single impurity: ≤ 0.1
Chiral isomer: ≤ 0.5%
The main purpose: antidepressants


Use
Duloxetine hydrochloride/Cymbaha (hereinafter referred to as duloxetine) is a 5-hydroxytryptamine and norepinephrine reuptake inhibitor developed by Eli Lilly. 5 Both serotonin and norepinephrine are central neurotransmitters and play an important role in regulating emotion and sensitivity to pain. Duloxetine can inhibit the reuptake of neurons to serotonin and norepinephrine, thereby increasing the concentration of these two central neurotransmitters in the brain and spinal cord. It can be used to treat certain mood disorders such as depression. And anxiety disorders and relieve central pain such as diabetic peripheral neuropathy pain and fibromyalgia in women. Duloxetine can also act on the 5-hydroxytryptamine and norepinephrine receptors in the urethra, thereby enhancing the neurological tone and contractility of the urinary sphincter, and is therefore effective in the treatment of stress urinary incontinence in women. Duloxetine is an oral enteric-coated capsule preparation. It was first approved in the United States in August 2004 and has now been marketed in more than 70 countries. The global sales of duloxetine exceeded US$1.3 billion in 2006, and its sales in 2007 and 2008 increased significantly to US$2.1 billion and US$2.7 billion, respectively, making it one of the fastest-growing drugs in the world in recent years. .


Application
In August and December 2004, the United States and the European Union approved duloxetine for the treatment of major adult depression. This is the first indication that duloxetine is officially approved for clinical use. A total of 512 subjects randomized, double-blind, placebo-controlled, pivotal study j1 showed that duloxetine was significantly lower than placebo at 17 weeks with 60 nag once-daily nausea. The total score of the table (tlDRS-17), and significantly improved depressive symptoms after 1 wk of treatment. Another study of 478 patients with severe depression in China, South Korea, and other countries confirmed that the efficacy of duloxetine 60 mg once a day to relieve depressive symptoms is at least comparable to the most commonly used selective serotonin reuptake One paroxetine/Paxii 20 mg/d was inhibited with fewer side effects (smaller) and did not cause weight gain and sexual dysfunction in the patient. In addition, duloxetine can also significantly improve physical symptoms in patients with depression, including insomnia, bradykinesia, pain, and headaches, which are usually those that cannot be achieved with the use of serotonin reuptake inhibitors. Duloxetine is expected to replace the serotonin reuptake inhibitor as a first-line choice for the treatment of major depression.


Taboo
Duloxetine metabolizes CYP2D6 and CYP1A2, moderately inhibits CYP2D6, but does not inhibit or induce CYP1A2 and CYP3A4. Care should be taken with other drugs that are primarily metabolized by CYP2D6 and have a narrow therapeutic window (eg, TCAs, Class Ic antiarrhythmic drugs, phenothiazines).
1. Disable patients who are known to be allergic to duloxetine or any inactive ingredient in the product. 2. The use of monoamine oxidase inhibitors must not be used in conjunction with the use of monoamine oxidase inhibitors. It is also not possible to use this product within 14 days after the withdrawal of monoamine oxidase inhibitors; according to the half-life of duloxetine, the use of MAOIs can be started at least 5 days after the withdrawal of duloxetine. 3. Clinically indicated that duloxetine increases the risk of dilated pupils, so patients with uncontrolled angle-closure glaucoma should avoid using duloxetine.


Competitive Advantage:

1. Best prices with satisfied quality, great quality and purity.
2. Perfect packing, rich experienced and safe, fast delivery.
3. Enough stock ensure the prompt delivery time .
4. Good after-sales service.


Others offering:
Tasimelteon/ Hetlioz 609799-22-6
Diphenhydramine HCl 147-24-0
Doxylamine Succinate 562-10-7
Melatonin 73-31-4
Zaleplon 151319-34-5
Suvorexant 1030377-33-3
Duloxetine HCl/ Cymbalta 136434-34-9
Quetiapine Fumarate/ Seroquel 111974-72-2
Bupropion HCl 31677-93-7
Citalopram Hydrobromide/ Celexa 59729-32-7
Escitalopram 219861-08-2
Fluvoxamine Maleate/ Luvox 61718-82-9
Paroxetine HCl/ PX/ POTH 78246-49-8
N-Methyl Paroxetine 110429-36-2
Zoloft/ Sertraline HCl 79559-97-0
Fluoxetine HCl/ Prozac 59333-67-4/56296-78-7
Clonidine HCl 4205-91-8
Mirtazapine/ Remeron 85650-52-8/ 61337-67-5
Armodafinil 112111-43-0
Tianeptine Sodium  30123-17-2
Tianeptine/ Stablon 66981-73-5
Tianeptine Sulfate 1224690-84-9
   
Trazodone HCl/ Desyrel 25332-39-2
Agomelatine 138112-76-2
Atomoxetine/ Strattera 82248-59-7
Amitriptyline HCl/ Elavil/ Endep 549-18-8
Reboxetine Mesylate 71620-89-8
Vilazodone 163521-12-8
Vilazodone HCl/ Viibryd 163521-08-2
Vortioxetine/ Trintellix/ Brintellix/ Lu AA21004 508233-74-7
Vortioxetine hydrobromide 960203-27-4
Milnacipran Hydrochloride/ Ixel/ Savella 101152-94-7
Levomilnacipran/ Fetzima 96847-55-1
Desvenlafaxine/ Pristiq (98%) 93413-62-8
Venlafaxine HCl/ Efexor XR 99300-78-4


Welcome inquiry and order samples, i'm Amy, if you want know more details, pls send email me

 

L-Amino Acids

L-Asparagine Price,L-Histidine Feed Grade,Histidine Factory

Puho Pharmaceutical Co., Limited , http://www.gzproteins.com

Posted on